{"id":84517,"date":"2026-03-26T15:00:00","date_gmt":"2026-03-26T15:00:00","guid":{"rendered":"https:\/\/www.cofb.org\/?p=84517"},"modified":"2026-03-30T11:41:39","modified_gmt":"2026-03-30T11:41:39","slug":"la-formulacio-representa-una-oportunitat-real-de-posicionament-i-rendibilitat","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/ca\/2026\/03\/26\/la-formulacio-representa-una-oportunitat-real-de-posicionament-i-rendibilitat\/","title":{"rendered":"La formulaci\u00f3 representa una oportunitat real de posicionament i rendibilitat"},"content":{"rendered":"\n<ul class=\"wp-block-list\">\n<li>La formulaci\u00f3 actua com un element de diferenciaci\u00f3 professional en un entorn cada vegada m\u00e9s tensionat pel preu i la compet\u00e8ncia. Permet recuperar un espai propi basat en el coneixement, la personalitzaci\u00f3 i la resoluci\u00f3 de problemes que la ind\u00fastria no cobreix<\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/03\/COFB_INFARMA-MADRID-2026_FORMULACIO_26032026.jpg\" target=\"_blank\" rel=\" noreferrer noopener\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"683\" src=\"https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/03\/COFB_INFARMA-MADRID-2026_FORMULACIO_26032026-1024x683.jpg\" alt=\"\" class=\"wp-image-84518\" srcset=\"https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/03\/COFB_INFARMA-MADRID-2026_FORMULACIO_26032026-1024x683.jpg 1024w, https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/03\/COFB_INFARMA-MADRID-2026_FORMULACIO_26032026-300x200.jpg 300w, https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/03\/COFB_INFARMA-MADRID-2026_FORMULACIO_26032026-768x512.jpg 768w, https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/03\/COFB_INFARMA-MADRID-2026_FORMULACIO_26032026-1536x1024.jpg 1536w, https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/03\/COFB_INFARMA-MADRID-2026_FORMULACIO_26032026-18x12.jpg 18w, https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/03\/COFB_INFARMA-MADRID-2026_FORMULACIO_26032026.jpg 2048w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p>Sota el t\u00edtol de la pon\u00e8ncia <strong>\u201cFormular \u00e9s rentable\u201d<\/strong>, <strong>Edgar Abarca Lach\u00e9n<\/strong> i <strong>Diego Marro<\/strong>, membres de la Junta Directiva de LASEMI, van debatre sobre la <strong>import\u00e0ncia estrat\u00e8gica de la formulaci\u00f3 magistral<\/strong>. Durant la tercera jornada d&#8217;<a href=\"https:\/\/www.infarma.es\/\" target=\"_blank\" rel=\"noreferrer noopener\">Infarma Madrid 2026<\/a>, els experts van explicar que aquesta eina no nom\u00e9s es presenta com un recurs assistencial \u00fanic, sin\u00f3 que tamb\u00e9 es planteja com una activitat sostenible dins del model actual de farm\u00e0cia. El debat va ser moderat per <strong>Elena Manso<\/strong>, vocal en funcions de Formulaci\u00f3 Magistral del Colegio Oficial de Farmac\u00e9uticos de Madrid (COFM), qui va destacar la creixent rellev\u00e0ncia d&#8217;aquesta pr\u00e0ctica en l&#8217;\u00e0mbit professional farmac\u00e8utic.<\/p>\n\n\n\n<p>En un entorn marcat per la pressi\u00f3 sobre els marges, la necessitat de diversificaci\u00f3 i la cerca de nous serveis professionals, la formulaci\u00f3 representa una oportunitat real de posicionament i rendibilitat.<\/p>\n\n\n\n<p><strong>\u00bfFormular \u00e9s rentable?<\/strong> Amb aquesta pregunta va comen\u00e7ar Edgar Abarca, farmac\u00e8utic i professor de Formulaci\u00f3 de Medicaments Individualitzats en el Grau de la Universitat San Jorge (USJ), la seva pon\u00e8ncia. No obstant aix\u00f2, la resposta, lluny de ser un simple \u201cs\u00ed\u201d o \u201cno\u201d, obre una perspectiva m\u00e9s \u00e0mplia. Perqu\u00e8, en realitat, no es tracta nom\u00e9s de formular o no formular.<\/p>\n\n\n\n<p>Segons aquest expert, \u201c\u00e9s igual si tens laboratori o no. Ja est\u00e0s dins del negoci. Tant si elabores f\u00f3rmules com si les derives a una altra farm\u00e0cia, la formulaci\u00f3 magistral t&#8217;afecta directament. <strong>La clau no est\u00e0 a fabricar, sin\u00f3 a entendre l&#8217;ecosistema i saber com posicionar-te dins d&#8217;ell<\/strong>\u201d.<\/p>\n\n\n\n<p>Un dels punts clau que es van abordar en la pon\u00e8ncia va ser que \u201cla formulaci\u00f3 magistral no \u00e9s \u00fanicament un proc\u00e9s t\u00e8cnic, sin\u00f3 un ecosistema en el qual participen metges (que prescriuen i col\u00b7laboren), farmac\u00e8utics (que gestionen i assessoren) i pacients (que reben solucions personalitzades i es fidelitzen). Tots formen un sistema en el qual cadasc\u00fa aporta i rep valor. <strong>La formulaci\u00f3 magistral uneix aquests tres actors i genera relacions duradores i rendibles i, sobretot, \u00e9s una eina estrat\u00e8gica<\/strong>\u201d, tal com va ressaltar aquest expert.<\/p>\n\n\n\n<p>Des de l&#8217;experi\u00e8ncia real en farm\u00e0cia comunit\u00e0ria, el missatge \u00e9s clar: la formulaci\u00f3 actua com un element de diferenciaci\u00f3 professional en un entorn cada vegada m\u00e9s tensionat pel preu i la compet\u00e8ncia. Permet recuperar un espai propi basat en el coneixement, la personalitzaci\u00f3 i la resoluci\u00f3 de problemes que la ind\u00fastria no cobreix.<\/p>\n\n\n\n<p>Per la seva banda, Diego Marro, expert en negoci farmac\u00e8utic i comunicaci\u00f3 professional en salut, va explicar que \u201cen termes econ\u00f2mics, l&#8217;impacte \u00e9s tangible. La formulaci\u00f3 aporta una rendibilitat directa, amb marges \u00e0mpliament superiors als d&#8217;un medicament d&#8217;especialitat equivalent. El pacient de formulaci\u00f3 presenta un tiquet mitj\u00e0 molt m\u00e9s alt que el client habitual de taulell, per\u00f2 tamb\u00e9 aporta una rendibilitat menys visible i, probablement, m\u00e9s rellevant: la fidelitzaci\u00f3\u201d.<\/p>\n\n\n\n<p>\u201cEl pacient de formulaci\u00f3 no \u00e9s un pacient qualsevol. \u00c9s un perfil complex \u2014cr\u00f2nic, pedi\u00e0tric o dermatol\u00f2gic\u2014 que necessita seguiment, confian\u00e7a i solucions a mida. I quan troba resposta, no nom\u00e9s torna, sin\u00f3 que recomana, confia i amplia la seva relaci\u00f3 amb la farm\u00e0cia\u201d. \u201cLa f\u00f3rmula no \u00e9s el negoci\u2026 \u00e9s la porta\u201d. A partir d&#8217;aqu\u00ed, segons Marro, es construeix una relaci\u00f3 de valor que transcendeix la dispensaci\u00f3 puntual: m\u00e9s consell, m\u00e9s serveis i m\u00e9s vincle.<\/p>\n\n\n\n<p>Fins i tot per a aquelles farm\u00e0cies que no elaboren f\u00f3rmules, el missatge \u00e9s igualment rellevant. Detectar necessitats no cobertes, col\u00b7laborar amb farm\u00e0cies formuladores i establir circuits de derivaci\u00f3 permet participar activament en aquest model. No estar en aquest circuit, adverteixen, s\u00ed que t\u00e9 un cost: perdre visibilitat, posicionament i pacients d&#8217;alt valor.<\/p>\n\n\n\n<p>Ambd\u00f3s experts coincideixen que \u201cles farm\u00e0cies que queden fora de l&#8217;ecosistema de formulaci\u00f3 no nom\u00e9s perden una l\u00ednia d&#8217;ingressos, sin\u00f3 tamb\u00e9 visibilitat, posicionament i pacients d&#8217;alt valor. La posici\u00f3 a la xarxa importa m\u00e9s que la capacitat t\u00e8cnica de fabricar\u201d.<\/p>\n\n\n\n<p>Cal destacar que el mercat de la formulaci\u00f3 magistral a Espanya creix any rere any i permet recuperar un espai propi basat en el coneixement, la personalitzaci\u00f3 i la resoluci\u00f3 de problemes que la ind\u00fastria no cobreix.<\/p>\n\n\n\n<p>Pel que fa a les barreres reals, subratllen que \u201cla falta de temps, el desconeixement t\u00e8cnic, la inseguretat o l&#8217;abs\u00e8ncia de relacions amb prescriptors\u201d. Davant d&#8217;aix\u00f2, es plantegen solucions pr\u00e0ctiques i aplicables des de l&#8217;endem\u00e0: identificar pacients susceptibles, teixir aliances amb formuladors i comunicar activament el valor del medicament individualitzat.<\/p>\n\n\n\n<p><strong>Durant la seva intervenci\u00f3, Abarca va insistir que \u201cla farm\u00e0cia del futur no es defineix per lo que t\u00e9 al laboratori, sin\u00f3 pel lloc que ocupa a la xarxa sanit\u00e0ria del seu entorn. El posicionament estrat\u00e8gic \u00e9s avui l&#8217;avantatge competitiu m\u00e9s durador<\/strong>\u201d.<\/p>\n\n\n\n<p>Finalment, va concloure que \u201cla formulaci\u00f3 magistral no \u00e9s una moda ni una especialitat de n\u00ednxol. \u00c9s el retorn a l&#8217;ess\u00e8ncia de la nostra professi\u00f3: con\u00e8ixer el pacient, entendre la seva necessitat i oferir una soluci\u00f3 \u00fanica, personalitzada i de valor. Aix\u00f2 \u00e9s farm\u00e0cia. Aix\u00f2 \u00e9s lo que ens diferencia\u00bb. Per tant, la formulaci\u00f3 magistral no \u00e9s una opci\u00f3: \u00e9s una oportunitat.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sota el t\u00edtol de la pon\u00e8ncia \u201cFormular \u00e9s rentable\u201d, Edgar Abarca Lach\u00e9n i Diego Marro, membres de la Junta Directiva de LASEMI, van debatre sobre la import\u00e0ncia estrat\u00e8gica de la formulaci\u00f3 magistral. Durant la tercera jornada d&#8217;Infarma Madrid 2026, els experts van explicar que aquesta eina no nom\u00e9s es presenta [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":84518,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[23,2165,1060],"tags":[5223,18,110,111,3989,68,154,28,508,5433,76],"class_list":["post-84517","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-destacats","category-infarma","category-notes-premsa","tag-closerstill-media","tag-cofb","tag-cofm","tag-congres","tag-congres-europeu-doficina-de-farmacia","tag-farmacia","tag-formulacio","tag-infarma","tag-infarma-madrid","tag-infarma-madrid-2026","tag-oficina-de-farmacia"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>La formulaci\u00f3 representa una oportunitat real de posicionament i rendibilitat - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cofb.org\/ca\/2026\/03\/26\/la-formulacio-representa-una-oportunitat-real-de-posicionament-i-rendibilitat\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"La formulaci\u00f3 representa una oportunitat real de posicionament i rendibilitat - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"Sota el t\u00edtol de la pon\u00e8ncia \u201cFormular \u00e9s rentable\u201d, Edgar Abarca Lach\u00e9n i Diego Marro, membres de la Junta Directiva de LASEMI, van debatre sobre la import\u00e0ncia estrat\u00e8gica de la formulaci\u00f3 magistral. Durant la tercera jornada d&#8217;Infarma Madrid 2026, els experts van explicar que aquesta eina no nom\u00e9s es presenta [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cofb.org\/ca\/2026\/03\/26\/la-formulacio-representa-una-oportunitat-real-de-posicionament-i-rendibilitat\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-26T15:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-30T11:41:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/03\/COFB_INFARMA-MADRID-2026_FORMULACIO_26032026.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2048\" \/>\n\t<meta property=\"og:image:height\" content=\"1365\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Berta Mart\u00ednez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"Berta Mart\u00ednez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.cofb.org\/2026\/03\/26\/la-formulacio-representa-una-oportunitat-real-de-posicionament-i-rendibilitat\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/2026\/03\/26\/la-formulacio-representa-una-oportunitat-real-de-posicionament-i-rendibilitat\/\"},\"author\":{\"name\":\"Berta Mart\u00ednez\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/f32de3b41b812c85ff923cb4cc849063\"},\"headline\":\"La formulaci\u00f3 representa una oportunitat real de posicionament i rendibilitat\",\"datePublished\":\"2026-03-26T15:00:00+00:00\",\"dateModified\":\"2026-03-30T11:41:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.cofb.org\/2026\/03\/26\/la-formulacio-representa-una-oportunitat-real-de-posicionament-i-rendibilitat\/\"},\"wordCount\":952,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/2026\/03\/26\/la-formulacio-representa-una-oportunitat-real-de-posicionament-i-rendibilitat\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/03\/COFB_INFARMA-MADRID-2026_FORMULACIO_26032026.jpg\",\"keywords\":[\"CloserStill Media\",\"COFB\",\"COFM\",\"Congr\u00e8s\",\"Congr\u00e9s europeu d'oficina de farm\u00e0cia\",\"Farm\u00e0cia\",\"formulaci\u00f3\",\"Infarma\",\"Infarma Madrid\",\"Infarma Madrid 2026\",\"Oficina de farm\u00e0cia\"],\"articleSection\":[\"Destacats\",\"Infarma\",\"Notes de premsa\"],\"inLanguage\":\"ca\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cofb.org\/2026\/03\/26\/la-formulacio-representa-una-oportunitat-real-de-posicionament-i-rendibilitat\/\",\"url\":\"https:\/\/www.cofb.org\/2026\/03\/26\/la-formulacio-representa-una-oportunitat-real-de-posicionament-i-rendibilitat\/\",\"name\":\"La formulaci\u00f3 representa una oportunitat real de posicionament i rendibilitat - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cofb.org\/2026\/03\/26\/la-formulacio-representa-una-oportunitat-real-de-posicionament-i-rendibilitat\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/2026\/03\/26\/la-formulacio-representa-una-oportunitat-real-de-posicionament-i-rendibilitat\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/03\/COFB_INFARMA-MADRID-2026_FORMULACIO_26032026.jpg\",\"datePublished\":\"2026-03-26T15:00:00+00:00\",\"dateModified\":\"2026-03-30T11:41:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cofb.org\/2026\/03\/26\/la-formulacio-representa-una-oportunitat-real-de-posicionament-i-rendibilitat\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cofb.org\/2026\/03\/26\/la-formulacio-representa-una-oportunitat-real-de-posicionament-i-rendibilitat\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/2026\/03\/26\/la-formulacio-representa-una-oportunitat-real-de-posicionament-i-rendibilitat\/#primaryimage\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/03\/COFB_INFARMA-MADRID-2026_FORMULACIO_26032026.jpg\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/03\/COFB_INFARMA-MADRID-2026_FORMULACIO_26032026.jpg\",\"width\":2048,\"height\":1365},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cofb.org\/2026\/03\/26\/la-formulacio-representa-una-oportunitat-real-de-posicionament-i-rendibilitat\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"La formulaci\u00f3 representa una oportunitat real de posicionament i rendibilitat\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/f32de3b41b812c85ff923cb4cc849063\",\"name\":\"Berta Mart\u00ednez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d4c584dab5da1ee9e3c3df161c0aabec7075cc8211cd46ffc79bfe177aa78b01?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d4c584dab5da1ee9e3c3df161c0aabec7075cc8211cd46ffc79bfe177aa78b01?s=96&d=mm&r=g\",\"caption\":\"Berta Mart\u00ednez\"},\"url\":\"https:\/\/www.cofb.org\/ca\/author\/bmartinez\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La formulaci\u00f3 representa una oportunitat real de posicionament i rendibilitat - Col\u00b7legi de Farmac\u00e8utics de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cofb.org\/ca\/2026\/03\/26\/la-formulacio-representa-una-oportunitat-real-de-posicionament-i-rendibilitat\/","og_locale":"ca_ES","og_type":"article","og_title":"La formulaci\u00f3 representa una oportunitat real de posicionament i rendibilitat - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"Sota el t\u00edtol de la pon\u00e8ncia \u201cFormular \u00e9s rentable\u201d, Edgar Abarca Lach\u00e9n i Diego Marro, membres de la Junta Directiva de LASEMI, van debatre sobre la import\u00e0ncia estrat\u00e8gica de la formulaci\u00f3 magistral. Durant la tercera jornada d&#8217;Infarma Madrid 2026, els experts van explicar que aquesta eina no nom\u00e9s es presenta [&hellip;]","og_url":"https:\/\/www.cofb.org\/ca\/2026\/03\/26\/la-formulacio-representa-una-oportunitat-real-de-posicionament-i-rendibilitat\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2026-03-26T15:00:00+00:00","article_modified_time":"2026-03-30T11:41:39+00:00","og_image":[{"width":2048,"height":1365,"url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/03\/COFB_INFARMA-MADRID-2026_FORMULACIO_26032026.jpg","type":"image\/jpeg"}],"author":"Berta Mart\u00ednez","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrit per":"Berta Mart\u00ednez","Temps estimat de lectura":"6 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cofb.org\/2026\/03\/26\/la-formulacio-representa-una-oportunitat-real-de-posicionament-i-rendibilitat\/#article","isPartOf":{"@id":"https:\/\/www.cofb.org\/2026\/03\/26\/la-formulacio-representa-una-oportunitat-real-de-posicionament-i-rendibilitat\/"},"author":{"name":"Berta Mart\u00ednez","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/f32de3b41b812c85ff923cb4cc849063"},"headline":"La formulaci\u00f3 representa una oportunitat real de posicionament i rendibilitat","datePublished":"2026-03-26T15:00:00+00:00","dateModified":"2026-03-30T11:41:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cofb.org\/2026\/03\/26\/la-formulacio-representa-una-oportunitat-real-de-posicionament-i-rendibilitat\/"},"wordCount":952,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/www.cofb.org\/2026\/03\/26\/la-formulacio-representa-una-oportunitat-real-de-posicionament-i-rendibilitat\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/03\/COFB_INFARMA-MADRID-2026_FORMULACIO_26032026.jpg","keywords":["CloserStill Media","COFB","COFM","Congr\u00e8s","Congr\u00e9s europeu d'oficina de farm\u00e0cia","Farm\u00e0cia","formulaci\u00f3","Infarma","Infarma Madrid","Infarma Madrid 2026","Oficina de farm\u00e0cia"],"articleSection":["Destacats","Infarma","Notes de premsa"],"inLanguage":"ca"},{"@type":"WebPage","@id":"https:\/\/www.cofb.org\/2026\/03\/26\/la-formulacio-representa-una-oportunitat-real-de-posicionament-i-rendibilitat\/","url":"https:\/\/www.cofb.org\/2026\/03\/26\/la-formulacio-representa-una-oportunitat-real-de-posicionament-i-rendibilitat\/","name":"La formulaci\u00f3 representa una oportunitat real de posicionament i rendibilitat - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cofb.org\/2026\/03\/26\/la-formulacio-representa-una-oportunitat-real-de-posicionament-i-rendibilitat\/#primaryimage"},"image":{"@id":"https:\/\/www.cofb.org\/2026\/03\/26\/la-formulacio-representa-una-oportunitat-real-de-posicionament-i-rendibilitat\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/03\/COFB_INFARMA-MADRID-2026_FORMULACIO_26032026.jpg","datePublished":"2026-03-26T15:00:00+00:00","dateModified":"2026-03-30T11:41:39+00:00","breadcrumb":{"@id":"https:\/\/www.cofb.org\/2026\/03\/26\/la-formulacio-representa-una-oportunitat-real-de-posicionament-i-rendibilitat\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cofb.org\/2026\/03\/26\/la-formulacio-representa-una-oportunitat-real-de-posicionament-i-rendibilitat\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/2026\/03\/26\/la-formulacio-representa-una-oportunitat-real-de-posicionament-i-rendibilitat\/#primaryimage","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/03\/COFB_INFARMA-MADRID-2026_FORMULACIO_26032026.jpg","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/03\/COFB_INFARMA-MADRID-2026_FORMULACIO_26032026.jpg","width":2048,"height":1365},{"@type":"BreadcrumbList","@id":"https:\/\/www.cofb.org\/2026\/03\/26\/la-formulacio-representa-una-oportunitat-real-de-posicionament-i-rendibilitat\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"La formulaci\u00f3 representa una oportunitat real de posicionament i rendibilitat"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/f32de3b41b812c85ff923cb4cc849063","name":"Berta Mart\u00ednez","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d4c584dab5da1ee9e3c3df161c0aabec7075cc8211cd46ffc79bfe177aa78b01?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d4c584dab5da1ee9e3c3df161c0aabec7075cc8211cd46ffc79bfe177aa78b01?s=96&d=mm&r=g","caption":"Berta Mart\u00ednez"},"url":"https:\/\/www.cofb.org\/ca\/author\/bmartinez\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/03\/COFB_INFARMA-MADRID-2026_FORMULACIO_26032026.jpg",2048,1365,false],"thumbnail":["https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/03\/COFB_INFARMA-MADRID-2026_FORMULACIO_26032026-150x150.jpg",150,150,true],"medium":["https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/03\/COFB_INFARMA-MADRID-2026_FORMULACIO_26032026-300x200.jpg",300,200,true],"medium_large":["https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/03\/COFB_INFARMA-MADRID-2026_FORMULACIO_26032026-768x512.jpg",768,512,true],"large":["https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/03\/COFB_INFARMA-MADRID-2026_FORMULACIO_26032026-1024x683.jpg",1024,683,true],"1536x1536":["https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/03\/COFB_INFARMA-MADRID-2026_FORMULACIO_26032026-1536x1024.jpg",1536,1024,true],"2048x2048":["https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/03\/COFB_INFARMA-MADRID-2026_FORMULACIO_26032026.jpg",2048,1365,false],"trp-custom-language-flag":["https:\/\/www.cofb.org\/wp-content\/uploads\/2026\/03\/COFB_INFARMA-MADRID-2026_FORMULACIO_26032026-18x12.jpg",18,12,true]},"uagb_author_info":{"display_name":"Berta Mart\u00ednez","author_link":"https:\/\/www.cofb.org\/ca\/author\/bmartinez\/"},"uagb_comment_info":0,"uagb_excerpt":"Sota el t\u00edtol de la pon\u00e8ncia \u201cFormular \u00e9s rentable\u201d, Edgar Abarca Lach\u00e9n i Diego Marro, membres de la Junta Directiva de LASEMI, van debatre sobre la import\u00e0ncia estrat\u00e8gica de la formulaci\u00f3 magistral. Durant la tercera jornada d&#8217;Infarma Madrid 2026, els experts van explicar que aquesta eina no nom\u00e9s es presenta [&hellip;]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/84517","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/comments?post=84517"}],"version-history":[{"count":3,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/84517\/revisions"}],"predecessor-version":[{"id":84521,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/84517\/revisions\/84521"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/media\/84518"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/media?parent=84517"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/categories?post=84517"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/tags?post=84517"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}